BlackRock Amends Axsome Therapeutics Stake, Signals Continued Confidence
Ticker: AXSM · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1579428
| Field | Detail |
|---|---|
| Company | Axsome Therapeutics, INC. (AXSM) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still holds a big chunk of Axsome, signaling institutional confidence.**
AI Summary
BlackRock, Inc. filed an amended SC 13G/A on January 26, 2024, disclosing its ownership in Axsome Therapeutics, Inc. as of December 31, 2023. This filing, an Amendment No. 4, indicates BlackRock's continued significant, though passive, stake in the pharmaceutical company. This matters to investors because BlackRock is a major institutional investor, and its sustained position suggests confidence in Axsome's long-term prospects, potentially influencing other investors.
Why It Matters
This filing shows that a major institutional investor, BlackRock, maintains a significant position in Axsome Therapeutics, which can be seen as a vote of confidence in the company's future.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate risks or changes in company operations.
Analyst Insight
Investors should note BlackRock's continued passive stake in Axsome Therapeutics as a sign of institutional interest, but should conduct their own due diligence as this filing doesn't reveal any new strategic moves or changes in ownership percentage.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- Axsome Therapeutics, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G/A
- Amendment No. 4 (number) — the specific amendment number of the filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, specifically Amendment No. 4, filed under Rule 13d-1(b).
Who is the reporting person in this filing?
The reporting person in this filing is BlackRock, Inc., with a Central Index Key (CIK) of 0001364742.
What is the subject company whose securities are being reported?
The subject company is Axsome Therapeutics, Inc., with a Central Index Key (CIK) of 0001579428.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of Axsome Therapeutics, Inc. is 05464T104.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding Axsome Therapeutics, Inc. (AXSM).